H.C. Wainwright raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $12 from $11 and keeps a Buy rating on the shares following the Q4 report. The firm expects another clinical update on BDTX-1535 in Q2.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
Questions or Comments about the article? Write to editor@tipranks.com